The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.
Volkmar Mueller
Honoraria - Roche
Research Funding - Oncogene Science
Sabine Riethdorf
No relevant relationships to disclose
Brigitte Kathrin Rack
Research Funding - Roche; Veridex
Wolfgang Janni
Honoraria - Roche
Research Funding - Roche
Peter A. Fasching
No relevant relationships to disclose
Erich Solomayer
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Sabine Kasimir-Bauer
No relevant relationships to disclose
Klaus Pantel
No relevant relationships to disclose
Tanja N. Fehm
Honoraria - Roche
Research Funding - Veridex